Investors Presentation Solutions made in plastic

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 Investors Presentation Q3: Nine Month Figures 2014 / 2015 Solutions made in plastic

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 Content 1. Highlights of first nine months 2014 / 2015 2. Overview key figures (past 12 quarters) 3. Nine months sales revenues, EBITDA & EBIT 4. Cash flow 5. Consolidated statement 6. First nine months 2014 / 2015 what else happened 7. Our strategy & Investment highlights 8. Summary & Outlook Headquarter Balda AG, Bad Oeynhausen

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 1. Highlights of first nine months 2014 / 2015 Sales revenue increase of 21.4 % to EUR 61.9 million EBITDA continues positive operative trend EBIT slightly negative because of one-time extraordinary items in Q3 Higher demand of customer orders in both segments: Sales revenues of Europe segment have risen by 26.9 % Sales revenues of America segment have risen by 16.4 % Balda had a very intense search period in Q2 and Q3 for M&A targets Share of sales revenues of Balda AG regarding its markets Agriculture 2 % Electronics 45 % Europe 55 % America 4 % Automotive 4 % Eyewear 15 % Healthcare 75 % Source: FC 2013/2014 Balda proves organic growth strategy to be successful

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 2. Overview key figures Sales revenues 1 [in EUR million] 25 20 15 10 5 0 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2012 2012 / 2013 2013 / 2014 2014 / 2015 EBITDA 1 [in EUR million] 5 0-5 -10-15 EBIT 12 [in EUR million] 5 0-5 -10-15 1 2012 short fiscal year; Q1 and Q2 2012 / 2013 including BSM; Q3 2012 / 2013 until today including US-operations 2 EBIT in Q4 2012 / 2013 was affected by impairment losses of approx. EUR 10 million on investments of acquired US-companies; EBIT in Q4 2013 / 2014 was affected by restructuring measurements with effects of approx. EUR 2.3 million ; EBIT in Q3 2014 / 2015 strongly affected by one-time extraordinary items

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 3. Growth in first nine months 2014 / 2015 [in EUR million] 61.9 51.0 21.9 27.8 29.2 34.0 1.3 2.8-2.4-0.8 1 July 2013 31 March 2014 1 July 2014 31 March 2015 Sales revenues Europe Sales revenues America EBITDA EBIT

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 4. Cash flow of first nine months 2014 / 2015 [in EUR million] 88.0 7.6 1.6-0.08-43.5-89.0 1 July 2013 31 March 2014 1 July 2014 31 March 2015 Cash flow from operating activities Cash flow from investing activities Cash flow from financing activities

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 5. Consolidated statement as of 31 March 2015 Assets and Equity & Liabilities [in EUR million] 208.4 274.8 248.5 Assets Non-current assets include - Property, plant and equipment EUR 20.1 million - Financial investments contains money deposits (bonded loans) EUR 15.0 million Current assets divide in - Inventories EUR 12.8 million - Trade receivables EUR 13.0 million - Cash and cash-equivalents EUR 119.6 million - Short-term deposits EUR 62.5 million - Other EUR 0.5 million Financial resources amount to EUR 194.6 million 66.5 26.3 31 March 2015 Non-current assets Liabilities Current assets Equity Equity and liabilities Equity ratio is 90.4 % Liabilities include - Trade payables EUR 4.4 million - Advance payments received EUR 4.9 million - Other EUR 17.0 million

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 6. First nine months 2014 / 2015 what else happened Many positive meetings with (potential) clients and looking forward to receiving new orders As planned Dieter Brenken left Management Board in October 2014 Balda has come to terms with its past Due to this process Balda is currently coping with several lawsuits In January Balda relieved former management in the USA Innovation Day for customers was held in Bad Oeynhausen at the end of February Purchase of dosing system for liquid medications, including a patent, production line, tools and customer relationships

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 7. Our strategy & Investment highlights Our strategy Investment highlights To focus on the expansion of our existing strengths and to enlarge our technology competence We are well positioned in growth markets and able to profit of social trends We rigorously implement our strategy regarding efficiency and growth both across segments and markets We have a first-class customer base, excellent product know-how and a highly qualified team We plan to strengthen our position with further strategic acquisitions First-class equipped production sites in Germany and the USA Highest quality standards amongst others for medical technology and automotive industry High proportion of medical-technical products Acknowledged know-how in industrialization and automation Extremely reliable supplier Long-term customer relationships Financial power and independence enable further growth and internationalization

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 8. Summary & Outlook Balda is on track and proves to run operational Sales revenues higher than expected, EBIT slightly negative due to one-time extraordinary items Balda plans further growth, both Organical, with a solid increase of revenues over the course of the next years External, by acquiring a suitable candidate interesting targets were and are still reviewed Balda further intensifies sales activities and customer proximities Balda adjusts its guidance: Sales revenues expected to be between EUR 80 and 82 million now, but positive EBIT less likely Balda will grow organically and externally and enlarge international presence and ultimately its company value

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 Q&A-Session Solutions made in plastic

Investors Presentation, Q3: Nine Month Figures 2014 / 2015 Investors Presentation Half Year Figures 2014 / 2015 Thank you for your attention!